Explore our 🎯 Q1 2026 Psychedelic Pipeline Bullseye Charts.

Psychedelic Bulletin #192: Psychedelic Safety; Compass’ Lacklustre Long-Term Data; LSD Microdosing No Better than Placebo in ADHD

Pα+

Pα+ Psychedelic Bulletin #192: Psychedelic Safety; Compass’ Lacklustre Long-Term Data; LSD Microdosing No Better than Placebo in ADHD

  • Psychedelic Safety Takes Centre Stage in Berkeley
  • Selection Bias and Small Sample Size Hamper Compass’ Long-Term Psilocybin Data
  • Placebo Outperforms LSD in MindMed’s Microdosing Study for ADHD
  • Other Stories
  • atai Bets on Bitcoin
  • Potential Tweak to Ukrainian Law Could Permit Psychedelic Research
  • Elon Musk Talks Ketamine with Don Lemon
  • Governor of Virginia Vetoes Compass Pathways Rescheduling Bill

Psychedelic Safety Takes Centre Stage in Berkeley

Last week, I (Psychedelic Alpha Editor, Josh Hardman) attended the Psychedelic Safety Summit at my alma mater (well, year-abroad-mater), UC Berkeley. It was great to be back on campus, especially alongside a fantastic group of folks from across the psychedelics field.

Chatham House-type rules limit my reporting of specifics, with attributed remarks not permitted. The organisers were planning, I believe, to release a media-friendly report following each day of the summit, but that appears to have got lost in the shuffle that organising such a packed event entails.

The Summit, supported primarily by the Educational Foundation of America with additional contribution from the William G Nash Foundation, drew a diverse crowd of 150-odd. Those participants included psychedelic industry figures, researchers of various stripes, psychedelic harm reductionists, Indigenous people, government workers, and others.

Aside from the Summit participants, also in attendance were volunteers, ‘stewards’, and facilitators—all of which would have been worthy ‘participants’ themselves.

The organisers certainly did a good job of attracting such an impressive crowd, though some attendees wondered how that process had worked (the Summit did not accept applicants).

Join Today

Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and research.

Monthly $20 Annually $200
  • Regular Bulletins featuring news, analysis, and research
  • Articles and deep dives across psychedelic drug development, policy, and research
  • Exclusive interviews with researchers, executives, and policymakers
  • Bespoke resources and tools including the Psychedelic Bill Tracker
  • Quarterly video briefings and slide decks

Join Today

Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and research.

Monthly $20 Annually $200

Subscribe to our
free newsletter


By signing up, you agree to our privacy policy. You can unsubscribe at any time.

Learn More About

Group, team &
corporate plans


Aside from group pricing, we also offer bespoke reports and regular briefings. Get in touch to discuss.